A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors
The purpose of the study is to determine safety and tolerability of CVX-045 in patients with advanced solid tumors.
Advanced Solid Tumors|Neoplasms|Carcinoma|Cancer|Malignancy
BIOLOGICAL: CVX-045
To determine safety and tolerability of CVX-045 as weekly intravenous (IV) infusions in adult patients with advanced solid tumors, Throughout duration of study|To identify and characterize CVX-045-related adverse events (AEs), Throughout duration of study
To evaluate the plasma pharmacokinetics (PK) of CVX-045, Days 1, 4, 8, 15, 29|To determine a recommended Phase 2 dose of CVX-045, End of study|To evaluate the potential for immunogenicity of CVX-045, Days 1, 15, 1st day of every subsequent cycle, EOS, 30 Day FU|To document any preliminary evidence of antitumor activity, Every 8 weeks
The purpose of the study is to determine safety and tolerability of CVX-045 in patients with advanced solid tumors.